Roth Capital Remains Positive on Spectrum Pharma (SPPI) as Beleodaq Wins Accelerated Approval
Tweet Send to a Friend
Roth Capital affirms Spectrum Pharma (Nasdaq: SPPI) at Buy with a price target of $15 following news that Beleodaq received ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE